2-(3-(4-chlorophenyl)isoxazol-5-yl)ethanol | 27473-10-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-(4-chlorophenyl)isoxazol-5-yl)ethanol
• 英文别名: 2-[3-(4-chlorophenyl)-1,2-oxazol-5-yl]ethanol
• CAS: 27473-10-5
• 化学式: C₁₁H₁₀ClNO₂
• 分子量: 223.659
• InChiKey: XVWNLZSTGZYSEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-(4-chlorophenyl)isoxazol-5-yl)ethanol 、 甲基磺酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  DERIVATIVES OF ALKYLPIPERAZINE AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS

  摘要：

  本发明涉及烷基哌嗪和烷基同源哌嗪羧酸盐及其衍生物，其制备方法以及作为脂肪酸酰胺水解酶（FAAH）酶抑制剂的治疗用途。这些衍生物通过与大麻素和辣椒素受体等相互作用，发挥各种药理活性。通过抑制FAAH酶的代谢活性，通常导致疾病发作和其他病理状况的化合物不会生成，疾病的发生率大大降低。

  公开号：

  US20070027141A1
• 作为产物：
  描述：

  4-chlorobenzaldoxime 在 吡啶 、 N-氯代丁二酰亚胺 作用下， 以 aq. phosphate buffer 、 氯仿 、 丙酮 为溶剂， 生成 2-(3-(4-chlorophenyl)isoxazol-5-yl)ethanol
  参考文献：
  名称：

  水辅助氧化腈环加成反应：异恶唑的合成以及异恶唑啉和1,2,4-恶二唑的立体选择性合成

  摘要：

  常规方法是在碱性条件下由有机溶剂中的肟卤化物生成腈氧化物。但是，目前的工作表明，在弱酸性条件下（pH值为4-5）会进行水辅助生成的腈氧化物。在不使用催化剂的情况下，腈类化合物与炔烃和烯烃的环加成反应很容易在水中发生，因此分别制得异恶唑和异恶唑啉，对五元和六元环状烯烃具有出色的立体选择性。还实现了两个单元的腈与环己烯的双立体选择性环加成反应，从而得到具有独特的异恶唑啉-恶二唑骨架的1,2,4-恶二唑衍生物。从具有环应变的单萜制备对映体纯的异恶唑啉。在一种情况下，仅制备了蝴蝶状结构的异恶唑啉，

  DOI：

  10.1002/anie.201511730

文献信息

• Oxazole and isoxazole derivatives having anti-arthritic activity
  申请人：Hoffmann-La Roche Inc.

  公开号：US04774253A1

  公开（公告）日：1988-09-27

  Oxazole and isoxazole derivatives of the formula ##STR1## wherein A is C.sub.1-6 -alkylene, Het is a 2-R-oxazol-5-yl, 5-R-oxazol-2-yl, 4-R-oxazol-2-yl, 2-R-oxazol-4-yl, 3-R-isoxazol-5-yl or 5-R-isoxazol-3-yl group which is optionally substituted on the heterocyclic ring by a C.sub.1-6 -alkyl group, R is phenyl or thienyl monosubstituted or disubstituted by halogen, trifluoromethyl or C.sub.1-6 -alkylthio, R.sup.1 and R.sup.2 each is a C.sub.1-6 -alkyl group and R.sup.3 is a hydroxy or C.sub.1-6 -alkoxy group or a group of the formula --NR.sup.4 R.sup.5 in which R.sup.4 and R.sup.5 each is a hydrogen atom or a C.sub.1-6 -alkyl group or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached is a 5-membered or 6-membered saturated heteromonocyclic ring which may contain an oxygen or sulphur atom or an additional nitrogen atom, and pharmaceutically acceptable salts of the compounds of formula I in which R.sup.3 is a hydroxy group with bases, have anti-arthritic activity.

  式为##STR1##的噁唑和异噁唑衍生物，其中A是C.sub.1-6-烷基，Het是2-R-噁唑-5-基，5-R-噁唑-2-基，4-R-噁唑-2-基，2-R-噁唑-4-基，3-R-异噁唑-5-基或5-R-异噁唑-3-基，该基团在杂环上可以被C.sub.1-6-烷基取代，R是苯基或噻吩基，经卤素，三氟甲基或C.sub.1-6-烷基硫代取代的单取代或双取代，R.sup.1和R.sup.2各自是C.sub.1-6-烷基，R.sup.3是羟基或C.sub.1-6-烷氧基或公式--NR.sup.4 R.sup.5的基团，其中R.sup.4和R.sup.5各自是氢原子或C.sub.1-6-烷基或R.sup.4和R.sup.5与它们所连接的氮原子一起是一个5-成员或6-成员饱和杂环，该杂环可以包含一个氧原子或硫原子或额外的氮原子，以及公式I化合物的药学上可接受的盐，其中R.sup.3是羟基的化合物与碱有抗关节炎活性。
• Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors
  申请人：Sanofi-Aventis

  公开号：US07973042B2

  公开（公告）日：2011-07-05

  The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of disease and other pathological conditions are not generated and the incidence of the disease is greatly reduced.

  本发明包括烷基哌嗪和烷基同型哌嗪羧酸盐及其衍生物，其制备方法以及作为脂肪酸酰胺水解酶（FAAH）酶抑制剂的治疗用途。这些衍生物通过与大麻素和辣椒素受体等相互作用，发挥各种药理活性。通过抑制FAAH酶的代谢活性，通常导致疾病和其他病理状况的化合物不会生成，疾病的发生率大大降低。
• Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors
  申请人：Sanofi-Aventis

  公开号：US07482346B2

  公开（公告）日：2009-01-27

  The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of disease and other pathological conditions are not generated and the incidence of the disease is greatly reduced.

  本发明涉及烷基哌嗪和烷基同源哌嗪羧酸盐及其衍生物，它们的制备方法以及作为脂肪酸酰胺水解酶（FAAH）酶抑制剂的治疗用途。这些衍生物与大麻素和辣椒素受体等相互作用，发挥多种药理活性。通过抑制FAAH酶的代谢活性，通常导致疾病和其他病理状态发生的化合物不会生成，疾病的发生率大大降低。
• DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS
  申请人：Abouabdellah Ahmed

  公开号：US20090143365A1

  公开（公告）日：2009-06-04

  The present invention comprises alkylpiperazine- and alkylhomopiperazine carboxylates and their derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of disease and other pathological conditions are not generated and the incidence of the disease is greatly reduced.

  本发明涉及烷基哌嗪和烷基同型哌嗪羧酸盐及其衍生物，其制备方法以及作为脂肪酸酰胺水解酶（FAAH）酶抑制剂的治疗用途。这些衍生物通过与大麻素和辣椒素受体等相互作用，发挥各种药理活性。通过抑制FAAH酶的代谢活性，通常会导致疾病和其他病理状况的化合物不会生成，从而大大降低了疾病的发生率。
• Substituted Tetrahydropyrrolo[2,1-<i>b</i>]oxazol-5(6<i>H</i>)-ones and Tetrahydropyrrolo[2,1-<i>b</i>]thiazol-5(6<i>H</i>)-ones as Hypoglycemic Agents
  作者：Thomas D. Aicher、Bork Balkan、Philip A. Bell、Leonard J. Brand、S. H. Cheon、Rhonda O. Deems、Jay B. Fell、William S. Fillers、James D. Fraser、Jiaping Gao、Douglas C. Knorr、Gerald G. Kahle、Christina L. Leone、Jeffrey Nadelson、Ronald Simpson、Howard C. Smith

  DOI：10.1021/jm9803121

  日期：1998.11.1

  A series of substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones was synthesized from amino alcohols or amino thiols and keto acids. A pharmacological model based on the results obtained with these compounds led to the synthesis and evaluation of a series of isoxazoles and other monocyclic compounds. These were evaluated for their ability to enhance glucose utilization in cultured L6 myocytes. The in vivo hypoglycemic efficacy and potency of these compounds were evaluated in a model of type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), the ob/ob mouse. 25a(2S) (SDZ PGU 693) was selected for further pharmacological studies.